Full-Time

Director, Patient Services Strategy

Rare Nephrology

Updated on 8/17/2026

Deadline 9/4/26
Alexion

Alexion

5,001-10,000 employees

Global biopharmaceuticals focusing on rare diseases

No salary listed

Boston, MA, USA

In Person

Bachelor's

Category
Business & Strategy (1)
Required Skills
Data Governance
HIPAA

Get referred to Alexion

See people who can refer or advise you

Requirements
  • A Bachelor's Degree.
  • At least 8 years of pharmaceutical, biotechnology, or healthcare experience in the commercial space, with extensive industry knowledge.
  • Ability to align strategy across Patient Services, Brand Marketing, Market Access, and related functions, and represent senior leadership in cross-functional forums.
  • Experience setting key performance indicator targets, establishing operating cadences, and managing performance to outcomes.
  • Strong analytical skills and the ability to create and deliver executive-ready presentations.
  • Understanding of legal, privacy, and compliance considerations in Patient Services, including HIPAA, OIG, and CMS regulations, with experience establishing data and content guardrails.
  • Ability to use a computer and communicate via phone, video, and electronic messaging; engage in problem solving, analysis, and dialogue; collaborate with others; and maintain general availability during standard business hours.
  • Adaptability, self-directed learning, curiosity, feedback-seeking, accountability, patient centricity, and a positive mindset.
Responsibilities
  • Set the end-to-end Patient Services strategy for the Rare Nephrology portfolio across onboarding, access, initiation and adherence, and retention to support a successful patient journey.
  • Set frameworks and approval criteria for call guides, welcome kits, and above-brand materials developed by partner teams for use with patients.
  • Serve as a key member of the Rare Hematology/Nephrology Patient Services Leadership Team.
  • Partner cross-functionally to implement new initiatives, including material design and approval, training plans, and communication strategies.
  • Contribute to the Patient Services Innovation Roadmap by integrating innovation and artificial intelligence into ways of working for scalable, compliant execution.
  • Define the approach to external market dynamics and oversee consolidated reporting and insight synthesis to guide strategy updates.
  • Own strategy and design for future launches, including strategic allocation of each Patient Services role to indications within Rare Nephrology.
  • Establish key performance indicator targets and operating cadence; coordinate cross-functional performance reviews and recommend actions to senior leadership for continuous improvement.
  • Collaborate with the Rare Hematology Patient Services Strategy counterpart.
  • Coordinate and deliver Patient Services brand plans for the Rare Nephrology portfolio.
Desired Qualifications
  • Experience leading launch strategy and readiness planning for specialty or rare disease therapies.
  • Prior Patient Services leadership experience spanning strategy, governance, or cross-functional program management.
  • Ability to lead complex, multi-stakeholder initiatives from design through performance management.

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ultomiris received FDA priority review June 15, 2026 for IgA nephropathy.
  • Alexion advanced ALXN2220 into phase 3 for ATTR-CM on April 10, 2026.
  • AAN 2026 data highlighted gefurulimab, Koselugo, and Ultomiris across neurology indications.

What critics are saying

  • Epysqli, a Soliris biosimilar, won FDA approval July 22, 2026, crushing legacy margins.
  • Strensiq successor efzimfotase alfa missed the adult primary endpoint in March 2026.
  • Alexion remains exposed to Ultomiris concentration; one setback hits hematology, nephrology, and neurology growth.

What makes Alexion unique

  • Alexion built first-mover complement biology expertise and still leads C5 inhibition.
  • AstraZeneca gives Alexion global scale, capital, and regulatory reach in rare disease.
  • Its portfolio spans Soliris, Ultomiris, Strensiq, Kanuma, and emerging antibody modalities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

Mental Health Support

Wellness Program

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Relocation Assistance

Employee Referral Bonus

Meal Benefits

Commuter Benefits

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old